Imeglimin, a novel, first in-class, blood glucose-lowering agent: a systematic review and meta-analysis of clinical evidence

THOMAS SJ CRABTREE,1,2 RALPH A DEFRONZO,3 ROBERT EJ RYDER,2 CLIFFORD J BAILEY4

Abstract
Imeglimin is a novel, first in-class, blood glucose-lowering agent which acts via a mitochondrial mechanism to enhance glucose-induced insulin secretion, decrease hepatic glucose output and increase glucose uptake by skeletal muscle. A systematic review and meta-analysis of randomised controlled clinical trials (RCTs) with imeglimin in adults with type 2 diabetes was undertaken. Of 45 articles identified, five were RCTs but, due to the format of the data, only three could be combined in a meta-analysis (total n=180 participants). A random-effects model found that imeglimin 1500 mg twice daily as monotherapy and add-on to metformin or sitagliptin was associated with reductions of HbA1c by −0.63% (95% CI −0.84 to −0.42) (−6.6 mmol/mol, 95% CI −8.8 to −4.4) and reductions of fasting plasma glucose by −0.52 mmol/L (95% CI −0.80 to −0.24) compared with placebo. Adverse events were minimal, mostly gastrointestinal, and without hypoglycaemia. It is concluded that imeglimin displays promising improvements in HbA1c and fasting plasma glucose and is generally well tolerated.

Br J Diabetes 2020;20:28-31

Key words: type 2 diabetes; mitochondria; imeglimin; glimins; tetrahydrotriazine, systematic review, meta-analysis

Introduction
Type 2 diabetes is the product of multiple pathogenic factors including insulin resistance, beta-cell dysfunction and many other disturbances that underlie the development of hyperglycaemia. Current glucose-lowering medications taken as monotherapy or in combinations are often unable to reinstate normoglycaemia, indicating the need for new therapies with different modes of action. This paper focuses on imeglimin, a new type of glucose-lowering agent (a glimin) continuing after delays in phase 3 development for the treatment of type 2 diabetes.

Imeglimin is a tetrahydrotriazine that acts on mitochondria to increase flux through complex II of the respiratory chain, increasing ATP synthesis and reducing the production of reactive oxygen species. Mitochondrial dysfunction has been shown to play an important pathogenic role in the development of type 2 diabetes, and can be demonstrated in the normal, glucose-tolerant, insulin-resistant offspring of diabetic parents. Studies in animal models have shown that imeglimin impacts the pathophysiology of type 2 diabetes mellitus by improving glucose-induced insulin secretion, increasing beta-cell mass, decreasing hepatic glucose output and increasing skeletal muscle glucose uptake. Imeglimin may also protect endothelial cells from the effects of glucotoxicity with potential beneficial cardiovascular effects.

This systematic review and meta-analysis assesses the evidence from clinical trials of imeglimin compared with placebo or other established oral glucose-lowering drugs.

Methods
The word “imeglimin” was searched using the Ovid Medline and Embase databases and grey literature. Randomised controlled trials or cluster randomised controlled trials conducted with imeglimin against placebo and/or other oral glucose-lowering agents in human subjects were considered for inclusion. There were no restrictions of language or timeframe. Primary outcomes of interest for meta-analysis (where quantity and quality of data allowed) were HbA1c and fasting plasma glucose (FPG) following treatment with imeglimin. Secondary outcomes included adverse events and hypoglycaemia. Identified publications were assessed independently by two reviewers. A third reviewer was available but not required to adjudicate any disagreement over inclusions/exclusions. References listed in identified publications were cross-checked for any publications missed by the initial searches. All identified randomised controlled trials were assessed using the Cochrane risk of bias assessment. Data were extracted using Cochrane data collection forms. Outcomes of interest underwent random-effects analysis using RevMan 5.3. The review protocol was registered with PROSPERO prior to commencement (CRD42019155733).
Results

Of 45 articles identified by initial searches, three randomised controlled trials were accepted for meta-analysis of the primary outcomes of HbA1c and FPG (Figure 1). Two further identified studies were not included in the meta-analysis due to their use of placebo subtracted values rather than mean and SD for the individual arms. These will be discussed in the narrative. Baseline characteristics, study size, dose of imeglimin and follow-up of the five identified studies are shown in Table 1.

Primary outcomes

Baseline mean±SD values for HbA1c and FPG in the three included studies were 8.2±0.6% (66±7 mmol/mol) and 10.3±1.9 mmol/L, respectively. The meta-analyses of HbA1c and FPG data from the three included studies are shown in Figure 2, along with risk of bias assessment for these studies.12–14 The random-effects model determined that imeglimin 1500 mg twice daily was associated with reductions of HbA1c of −0.63% (95% CI −0.84 to −0.42) (−6.6 mmol/mol, 95% CI −8.8 to −4.4) and reductions of FPG by −0.52 mmol/L (95% CI −0.80 to −0.24) compared with placebo.

Two studies not included in the meta-analysis showed significant placebo-subtracted decreases in HbA1c and FPG with imeglimin.15 16 In a 24-week phase 2b monotherapy trial with 299 Japanese patients, imeglimin (1500 mg twice daily) was associated with placebo-corrected reductions of HbA1c (by −1.0%) (−11 mmol/mol) and FPG (by −1.4 mmol/L). In the recent 24-week phase 3 monotherapy trial, placebo-corrected reductions in HbA1c and FPG amongst 213 participants were −0.87% (−9 mmol/mol) and −1.1 mmol/L, respectively, with imeglimin (1000 mg twice daily). Each of these results was significant to p<0.001, but the confidence intervals or variances were not reported.

Secondary outcomes

Numerically fewer treatment-emergent adverse events were noted with imeglimin compared with placebo in two of the three included studies,12,14 and a small increase (3.9%) was noted in the other study.13 None of these events was considered serious, and the most common side effects were gastrointestinal, affecting ≤6% of patients taking imeglimin where reported.12,14 No adverse cardiovascular events were noted.

Hypoglycaemia (severity not defined) was noted on four occasions in one study during the run-in phase (ie, before commencing imeglimin),14 but no hypoglycaemia events were identified with imeglimin in this or any of the other studies. One study noted a ‘slight decrease’ in weight when participants received imeglimin in combination with metformin compared with metformin alone.13 No other studies reported body weight outcome.

Discussion

The present meta-analysis confirms that the novel glucose-lowering agent imeglimin consistently reduced HbA1c and FPG during randomised controlled trials in type 2 diabetes patients when used either as monotherapy or add-on to metformin or sitagliptin. Overall reductions of HbA1c (by 0.63%) and FPG (by 0.52 mmol/L) with the 1500 mg twice daily dose of imeglimin are comparable with efficacy data reported for some other classes of glucose-lowering agents such as dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors.17

Adverse effects were mostly minor and related to the gastrointestinal tract, indicating that imeglimin was generally well tolerated. Severe hypoglycaemia was not identified with imeglimin, consistent with agents that exhibit similar glucose-lowering efficacy.17 However, evidence from larger studies will be required to confirm this. Further evidence of the effect of imeglimin on body weight is also needed.
Table 1: Characteristics and main findings of randomised controlled studies identified from systematic searches assessing imeglimin versus placebo included in systematic review

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Participants</th>
<th>Arms</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pirags et al, 201212</td>
<td>8-week, multicentre, randomised, four-arm parallel group study. Patients on no other therapy</td>
<td>n=95 Mean age in imeglimin group 1500 mg BD group 60.0 years Mean BMI in imeglimin group 32.2 kg/m² All arms were broadly similar</td>
<td>Patients randomised to imeglimin 500 mg BD; imeglimin 1500 mg BD; metformin 850 mg BD or placebo</td>
<td>Imeglimin 1500 mg BD Changed HbA₁c −0.18% vs +0.31% vs placebo. Changed FPG −1.02 mmol/L vs +0.37 mmol/L in placebo Fewer adverse events with imeglimin vs placebo Adverse events mostly GI</td>
</tr>
<tr>
<td>Fouqueray et al, 201313</td>
<td>12-week, multicentre, randomised, double-blind, placebo controlled, parallel group study. Patients inadequately controlled on maximum dose of metformin</td>
<td>n=156 Age range 18-70 years BMI not reported</td>
<td>Patients randomised to combination therapy with metformin + imeglimin 1500 mg BD vs placebo + metformin</td>
<td>Imeglimin 1500 mg BD Changed HbA₁c −0.65% vs −0.21% vs placebo. Changed FPG −0.91 mmol/L vs +0.36 mmol/L in placebo Numerical increase (3.9%) of patients with adverse events with imeglimin vs placebo “Slight decrease” in body weight observed</td>
</tr>
<tr>
<td>Fouqueray et al, 201414</td>
<td>12-week, multicentre, randomised, double-blind, placebo controlled, parallel group study. Patients inadequately controlled on sitagliptin alone.</td>
<td>n=170 Age range 18-75 years BMI 20-40 kg/m²</td>
<td>Patients randomised to combination therapy with sitagliptin + imeglimin 1500 mg BD vs placebo + sitagliptin</td>
<td>Imeglimin 1500 mg BD Changed HbA₁c −0.6% vs +0.12% in placebo Changed FPG −0.93 mmol/L vs −0.11 mmol/L in placebo Fewer adverse events with imeglimin vs placebo</td>
</tr>
<tr>
<td>Dubourg et al, 201715</td>
<td>24-week, multicentre, randomised, double-blind, placebo controlled trial. Japanese patients on no other therapy.</td>
<td>n=299 Mean age in imeglimin group 1500 mg BD group 57.6 years Mean BMI in imeglimin 1500 mg BD group 26.8 kg/m² All arms broadly similar</td>
<td>Patients were randomised to imeglimin 500 mg BD, imeglimin 600 mg BD, imeglimin 1500 mg BD or placebo</td>
<td>Imeglimin 1500 mg BD Placebo corrected reduction in HbA₁c −1.0% Placebo corrected reduction in FPG −1.4 mmol</td>
</tr>
<tr>
<td>TIMES 1 trial16</td>
<td>Topline results as per Poxel Website</td>
<td>n=213 Baseline characteristics not available</td>
<td>Patients were randomised to imeglimin 1000 mg BD or placebo</td>
<td>Imeglimin 1000 mg BD Placebo corrected reduction in HbA₁c −0.87% Placebo corrected reduction in FPG −1.1 mmol</td>
</tr>
</tbody>
</table>

*Not included in meta-analysis due to variation in format of reported outcomes. BD, twice daily; BMI, body mass index; FPG, fasting plasma glucose; GI, gastrointestinal.

Figure 2: Forest plot of meta-analysis of imeglimin versus placebo for (a) HbA₁c (%) and (b) fasting plasma glucose (mmol/L) using a random-effect model. Risk of bias assessment is included.

(1) SD absent therefore average variance of other studies used in lieu (this is likely an overestimate of variance given Figure 2 in original paper)
Imeglimin is a novel, first-in-class, glucose-lowering agent for the management of type 2 diabetes. Initial clinical trials show that imeglimin reduces HbA1c and fasting plasma glucose in type 2 diabetes, and is generally well tolerated.

The bias assessment noted insufficient information about the allocation process and incomplete data that precluded more extensive analyses. Other limitations concerned the modest numbers of patients, the duration of the trials (longest 24 weeks) and the need for studies that assess the effects of imeglimin in different groups of type 2 diabetes patients. These should consider different ethnicities and co-morbidities, different stages of disease progression and different combinations of agents, including measures of long-term efficacy and safety.

These initial trials indicate that imeglimin exerts a significant glucose-lowering effect as monotherapy or in combination with metformin or sitagliptin, achieving comparable efficacy with some other classes of glucose-lowering agents. Imeglimin was well tolerated and showed an acceptable safety profile in studies to date. Larger, longer and more detailed trials are awaited to expand present information.


Funding  None.

References